Page 1,500«..1020..1,4991,5001,5011,502..1,5101,520..»

For disabled vet, battle rages on as feds deny disability payments – Rapid City Journal

Posted: August 6, 2017 at 5:43 am

For 31-year-old Wayne Swier, a U.S. Army combat veteran who suffered devastating injuries from an improvised explosive device seven years ago in Afghanistan, this summer should have been a season of solace and celebration.

But fate and a federal agency seemed to have conspired to turn it into a nightmare.

Swier is set to marry his sweetheart in a week, and the couple plans to move into a new home near Johnson Siding built by the nonprofit Homes for Our Troops later in August.

By any account, it should be a summer of love for the Stephens High School graduate who spent the better part of two tours with the 101st Airbornes Band of Brothers unit fighting the Taliban in the remote mountainous regions of Afghanistan.

Instead, in May the Social Security Administration deemed him no longer disabled and cut off his monthly disability checks, in a manner as harsh as the way that IED blew off his leg in a small Afghan village in November 2010.

Today, Swier is essentially broke, behind on his rent, his credit cards are maxed out, and just last week, power was cut off to his Box Elder rental home due to nonpayment, meaning he couldnt even recharge his robotic prosthetic leg. Although his electricity has since been restored thanks to Black Hills Energy, the mans problems have not been resolved.

Somehow I was deemed no longer disabled by Social Security, and its been an absolute hellish nightmare, he said last week. I wish I wasnt disabled and that my leg grew back, and that my arm functioned, and that my gonads hadnt been blown off and I no longer needed testosterone shots, and I could hear, and I didnt have PTSD, and that I didnt have a traumatic brain injury," Swier said.

I wish I was magically cured and whole again.

Swiers life changed Nov. 13, 2010, when, according to him, his platoons gung-ho green lieutenant, heading into his first firefight, was too stubborn to heed advice from battle-tested subordinates. Instead of choosing a safer, less obvious route to a school in an Afghan town, the lieutenant ordered the platoon to use the road.

One moment, Swier was a 6-foot-5, 189-pound, physically fit soldier on a mission; the next, he was crumpled on the ground, his body ripped apart by the concussion and shrapnel of an improvised explosive device buried in the road.

The IED blast took his left leg, smashed into his left arm and left side, cleaved his testicles and nearly severed his left ear.

Following that devastating day, Swier spent two years confined to Walter Reed Army Medical Center in Washington, D.C., undergoing surgeries, participating in painful rehabilitation sessions and being fitted with the latest in a high-tech prosthesis he will wear for the rest of his life.

Midway through his rehabilitation at Walter Reed, Swier was fitted with an advanced Otto Bock X2 prosthetic leg made of titanium-carbon fiber and equipped with a microprocessor, a computer that senses his weight distribution and motion. Days later, the disabled vet took his first steps in many months.

It was like what I remembered walking to be like," the soft-spoken Swier recalled in a 2014 interview with the Journal.

But his battle on the homefront didnt end there. Two months after being discharged from Walter Reed and returning to the Black Hills, Swiers computerized leg stopped working and his new battle began with the Veterans Affairs federal agency.

He delivered the prosthesis to the Veterans Administration facilities at Fort Meade in Sturgis. Nearly two months later, when the VA hadnt informed him his prosthetic leg had been fixed, he returned to the federal facility, only to learn that the VA had set the device aside in a storage room and never sent it off for repair.

Frustrated, Swier overnighted the artificial limb to a specialist at Walter Reed who quickly identified the problem and fixed a simple short in a wire. Swier had it back in four days.

Now, the bearded, battle-tested vet is forced to face a new enemy in the form of a federal agency that inexplicably discontinued his $1,600 to $1,800 monthly disability stipend on which he relies, and which he has regularly received since 2011.

Its surreal and overwhelming, Swier said on Thursday. Its not like my leg grew back.

After repeated visits to the Social Security office in Rapid City, which still had not updated his contact information as of last week, Swier and his fiance, Bridget Marshall, a paraprofessional in the Rapid City school system, contacted the offices of U.S. Sen. John Thune and U.S. Rep. Kristi Noem. Both of those congressional offices continue to work on Swiers issue, but he still has not received his disability checks.

Originally told by Social Security workers that it would take a few months to resolve the issue and get Swier back on the disability designation, the couple was later told that, due to congressional office inquiries, it might now take six to eight months to correct the problem.

Im willing to take my leg off and set it on someones desk if it would speed the process, Swier said. Meanwhile, we wait.

Swier may never have enlisted a more passionate partner for his latest battle than his fiance, a mother of five who still has three kids at home. Shes told others of their problems on several social media outlets and said she was most concerned about her future husband, who made a commitment to his country and was being disrespected and humiliated by a government that is now not honoring its responsibilities to him.

I understand systems dont always work, but the lack of humanity, compassion and care has been the most painful part, Bridget said. My soon-to-be husband took an oath, and in turn, the government made an oath to him."

She said she will continue to fight for Swier and his hard-earned benefits.

Maybe Im someone who thinks they can change the world, but Im just hoping this will change something, she said of their combined battle with the Social Security bureaucracy.

Throughout their recent struggles, both federal and financial, Bridget said she has come to adore the man she met at a VFW meeting a year ago and whom she will marry Aug. 5 in Pierre.

I love that even though he has seen the worst of the worst, he looks for the best and the beauty in everyone, she said. He is grateful for all he has and he is resilient. He has such a lack of bitterness, something I dont think I could carry in my heart. He is so incredibly loving, compassionate, intelligent and humble.

Get news headlines sent daily to your inbox

Marshall said she wanted to thank Thune and Noems staffs for assistance, as well as members of the Combat Veterans Motorcycle Association for being there to assist Swier on his bad days.

Josh Crump, a retired Air Force serviceman who spent two tours in Afghanistan and now serves as executive officer for the 65-member Motorcycle Association in South Dakota, said hed become friends with Swier and had little doubt he remains 100 percent disabled.

Theres no question that Wayne is disabled. Ive ridden with him and I know hes disabled, Crump said. They wouldnt build him a home, ADA compliant, if he wasnt disabled.

Crump said he had encouraged Swier, a guy who would give you the shirt off his back, to call his congressional offices when he learned of his issues with Social Security.

The biggest thing with Waynes situation is, we come off the street, we volunteer to join the military and we basically write a check to the federal government telling them well do what you tell us to do and basically, in return, they need to take care of these servicemen and women, Crump said. But people sitting behind a desk are making these decisions, and theyre not helping anybody."

He said Swier has made a valiant sacrifice for his nation.

Waynes made a huge sacrifice, he added. We all signed up with the understanding we could get injured or killed, and were fine with that. But he gave up part of his brain and his leg in service to our country.

Contacted Thursday about Swiers issue, Sen. Thunes office cited privacy concerns related to constituent complaints in which the senators office is involved, but a representative encouraged those with similar issues to contact the senator's office.

My offices in South Dakota and Washington, D.C., are frequently contacted by people from around the state, Thune said in an email statement sent to the Journal. Fortunately, the professional and dedicated staff members who work on behalf of all South Dakotans are well-trained in handling a variety of cases, and they are committed to assisting people when they encounter problems with federal agencies or federally funded programs.

Meanwhile, a manager in the Rapid City Social Security office, who asked not to be named, said Thursday he would personally look into Swiers complaints and call the disabled veteran that day.

I honestly would like to look at the case itself, because there could be so many factors and so many things come into play, he said. I wouldnt want to speculate, but I would like to call him, Id like to review his records and see if we can get this straightened out.

Noting that Social Security has special processing for wounded warriors, the administrator referred further questions to the agencys press office. Later on Thursday, he asked that questions about Swiers case be put in writing, which they were.

As of Friday afternoon, the Journal had not received answers from the agency to the queries it had provided a day earlier.

But Swier did receive a call from Social Security on Thursday afternoon to confirm his status as 100 percent disabled. The representative said the agency had received his medical files, which total more than 8,000 pages, and had his case under review.

I think they will continue to make us play the waiting game, Swier said following the call. Its out of my hands. Im not in control of this. I just need to play their game and ride the wave.

Originally posted here:
For disabled vet, battle rages on as feds deny disability payments - Rapid City Journal

Posted in Testosterone Shots | Comments Off on For disabled vet, battle rages on as feds deny disability payments – Rapid City Journal

Trail Camera Trophies: Velvet deer, turkeys photographed on Topekan’s property – Topeka Capital Journal

Posted: August 6, 2017 at 5:43 am

For quite some time, I had been posting submitted photographs of deer, turkeys and other animals captured on trail cameras to my Rouse Outdoors blog on CJOnline.

Ive come to the realization that they are more likely to be seen by outdoors enthusiasts if they are listed in the actual Outdoors section of our website, so Im going to be running them as regular columns from now on with the header Trail Camera Trophies. Ill likely post some of the photographs in the print section, as well, so keep your eyes peeled for some great, candid shots of natures delights.

I received several great photographs recently from Dale Hossfeld, a longtime reader who frequently sends me trail camera photos and video he captures on his property in Topeka. This time, he sent a few photos of a velvet buck he snapped on his digital camera, instead.

The deer is seen wandering around near a piece of lawn art that you may have seen in some of his other photographs, and in one of the photos you can see the heads of two turkeys that appear to be photobombing the buck.

The velvet seen on this bucks antlers is actually a hairy skin that covers antlers as they grow in each spring and summer. The antlers are full of nerves and blood vessels, so this helps protect the spongy antlers before the deers testosterone begins to increase toward the end of the summer, causing the antlers to harden. The bucks will begin to shed their velvet by scraping their antlers against trees, which they do year-round regardless of whether theyre in velvet or not. The hard antlers will remain through the end of the breeding season before falling off, or being shed, in the winter or early spring. The cycle then starts all over again, with deer beginning to grow their velvety antlers again toward the middle or end of spring.

Read the original post:
Trail Camera Trophies: Velvet deer, turkeys photographed on Topekan's property - Topeka Capital Journal

Posted in Testosterone Shots | Comments Off on Trail Camera Trophies: Velvet deer, turkeys photographed on Topekan’s property – Topeka Capital Journal

We’ve got to talk: The militarization of biotechnology – Bulletin of the Atomic Scientists

Posted: August 6, 2017 at 5:42 am

Debate about the security implications of cutting-edge biotechnology is afflicted with a fundamental blind spota lack of attention to growing military interest in the field. This blind spot is evident in discussions about, for example, gene-editing technology (in relation both to gene drives and to human modification). Such debate has tended to focus on the idea that research and technology might be directly misused by the bad guysand has tended to ignore broader questions about how the ongoing militarization of cutting-edge fields in biology might contribute to insecurity.

Last year James Clapper, when he was US director of national intelligence, labelled emerging population-level genetic-modification techniques as potential weapons of mass destruction. A number of states, in the context of the Biological and Toxin Weapons Convention, have in recent years voiced concerns about state investment into biotechnology. Yet ethical reviews of gene editing to date in the United States have barely touched upon concerns about growing military interest in cutting-edge biotechas reflected in their absence from recent reports on both environmental and human modificationbiotechnology. Such omissions are in keeping with broad trends where US discussions about the potential for misusing biotechnology are concerned.

To be sure, the risk that benignly intended innovations might be directly misused by terrorists is a legitimate, if often overblown, security concern. But other issues merit concern as well. One such issue is the risk that military investment in biotechnology will adversely affect research priorities. Another is the possibility that military investment into defensive or public health projects by one state might be misinterpreted by other states as having offensive potential.

In the same vein, the scarcity of publicly available information about military research into biotechnology might fuel public distrust of valuable and well-intended work. It is clear, for example, that research into preventing, identifying, and treating infectious diseases by various militaries around the world will continue to provide broader spin-off benefitsbut publics in some states might be unsure why military rather than public health institutions lead such work.

A path toward addressing these concerns has already been established by the synthetic biology communityespecially in terms of its preemptive engagement with the security concerns that scientists entertain. However, even in this arena there has been a hesitance to address the issue of militarization.

Synthetic biology as a security laboratory. Synthetic biology is a field of scientific and technological development that has greatly extended humankinds abilities to manipulate biological organisms and processes. While genetic modification techniques have existed since the 1970s, synthetic biology is allowing for much more ambitious projectsoffering new ways of getting to grips with the complexity of biology and of developing a wide range of new technologies.

A watershed moment for this field was the First International Meeting of Synthetic Biology (SB 1.0), held at MIT in 2004. Central to the vision of the scientists involved was radically modifying naturally occurring organisms and processes through the application of engineering principles; the undertaking involved the convergence of a range of fields, including genetic engineering and computing. The appeal of the synthetic biology vision was broadand a number of subfields emerged under the synthetic biology banner in both the United States and Europe. Private and public investors committed significant resources to the establishment of research centers and networks, as well as to the development and commercialization of foundational technologies such as gene synthesis. This investment contributed to a number of early successes and landmark initiatives.

The initiatives included the establishment of a digital BioBricks repository, which today contains the genetic sequences of some 20,000 standardized biological parts, such as proteins that are involved in gene-expression within bacteria. This repository was established as a means for scientists to assert discovery rights, while also allowing for the rapid sharing and reuse of these discoveries by others. These biological parts are developed and utilized by the synthetic biology research community and in an annual student competition that showcases both the potential applications of research in the field and the rate at which the technology is advancing. Last years winners included a team based at Imperial College London that developed a tool to help scientists engineer production systems using multiple types of cells, a German team working on biological tissue printing, and a Chinese team that developed a design to detect poisons in traditional medicines.

Since its inception, synthetic biology has been a darling of scientific journalismwhich has made it challenging for civil society and regulators, when thinking through the fields societal implications, to separate hype from reality. Synthetic biology has also become symbolic of deeper questions about the way that science is supported and governed. The issues have included broad transformations in how societies engage with innovation, an increased emphasis on the need to open up the innovation process to public scrutiny, and the need for science to be more responsive to public needs. Security concerns have been a consistent aspect of these broader debates.

In no small part, this is a consequence of synthetic biologys having been established in the United States shortly after the 9/11 and Amerithrax attacks. At the time, regulators and funders in the United States were twitchy about the actual and perceived security concerns surrounding this fledgling field. The National Science Foundation, a major early investor in synthetic biology, set engagement with biosecurity concerns as a prerequisite for funding. The FBI, following through on recommendations by a blue-ribbon biosecurity board on synthetic biology, has also taken a proactive approach to reaching out to the community. The lead agent on this issue, Edward You, was recently profiledby MIT Technology Review as Americas Top Bioterror Cop.

Another key factor in the synthetic biology communitys continued engagement with security issues has been the commitment of prominent scientists. Stanford University bioengineering professor Drew Endy, who has been involved in numerous reviews of the field, has also been a leading advocate for biosecurity engagement by the next generation of synthetic biologists. Endy established the annual i-GEM competition (the acronym stands for international genetically engineered machine). This team competition for students includes a biosecurity review process providing young scientists an opportunity to consider the potential security implications of their work. Harvard University synthetic biologist George Church has also been a notable contributor on these issues. His public provocations over the years have repeatedly kick-started public debate. In addition, a number of social scientists have formed enduring professional relationships with practitioners of synthetic biologyand much of their work has focused on changing the way that scientists engage with potential risks and with the public.

The synthetic biology community has been central to the most intensive debate about the misuse of civilian biotechnology ever seena debate that has been under way since at least 2003. Engagement by scientists, civil society, funders, and regulators has spurred a raft of technology assessment initiatives and regulatory reviews in both the United States and Europe. In addition, the integration of ethical and security review into I-GEM, the annual undergraduate competition, has sensitized a generation of scientists to questions about their societal roles. Such initiatives have also helped raise the bar for some newer fields. Xenobiology, for exampleoriginally a subfield of synthetic biologyis currently seeking to establish its own disciplinary identity, and security implications are already being discussed as that fields research agenda is set. The security engagement displayed by the synthetic biology community appears to be catching.

At the same time, its important to remember the limitations that such communities face. Scientists envision and design techno-scientific fieldsbut they are subject to the whims of national-level funders and regulators. Its also very difficult for scientists to control how a technology will be used and commodified once the cat is out of the lab. This was illustrated at a recent synthetic biology meeting in Singapore. Endy, in his opening remarks, presented an egalitarian vision for future industrialization of synthetic biology technologies. But Randal J. Kirk, chairman of the biotech firm Intrexon (the main industry sponsor of the conference), delivered a slick presentation that provided a much more corporate vision of the fields future. This was a reminder of the central role that the market will play in synthetic biology investmentand of the role that industry will increasingly play in shaping regulation and public understanding of this area of biotechnology.

Jane Calvert, a University of Edinburgh social scientist who has been working in synthetic biology for over a decade, argued at the Singapore meeting that the field is closing as a creative spacethat the parameters of success are narrowing around what is commercially viable. Military involvement in synthetic biology presents similar dynamicsand discussions of this issue throughout biotechnology need to be promoted and internationalized. Military involvement in technology is not a bad thingand it is also inevitable. Still, legitimate concerns surround the ability of the military sector to skew research priorities. And of course, military involvement could also signal attempts to harness new biotechnology for hostile purposes. In those nations leading the way in terms of innovation, scientists might need to help ensure greater transparency regarding the scope and purposes of military investment in their fields.

Work in synthetic biology has created a community of scientists sensitized to such issues and willing to discuss them. The focus of discussion, however, needs to broaden beyond the national-level security preoccupations that currently dominate. One step in this direction would be to establish international dialogue among scientists specifically on the issue of biotechnology militarization. Such debates should not be limited to the existing preoccupation with pathogens, but rather should cover broader areas of military investment. This sort of dialogue might allow shared principles regarding state investment in biotechnology to be identified and articulatedprinciples that would both guide research priorities and establish hard limits about what is permissible. Such discussions could draw upon relevant principles in international human rights, humanitarian, and arms control lawincluding, but not limited to, treaties specifically dealing with biological, chemical, and environmental warfare. Such an outcome would give scientists a louder voice in conversations about military involvement in biotechnologywhile also reducing the stigma associated with invaluable military research and reinforcing the stigma against the weaponization of biotechnology.

See the article here:
We've got to talk: The militarization of biotechnology - Bulletin of the Atomic Scientists

Posted in Biotechnology | Comments Off on We’ve got to talk: The militarization of biotechnology – Bulletin of the Atomic Scientists

NJSBA magazine explores biotechnology and genetics – Yahoo News

Posted: August 6, 2017 at 5:42 am

The August issue of the New Jersey State Bar Association's bi-monthly magazine, New Jersey Lawyer, focuses on the evolving topic of biotechnology, genetics and the law.

"Although a very specialized area, biotechnology law crosses many legal disciplines, including litigation, licensing, intellectual property, patents, agriculture, business, venture capitalism, antitrust, biosecurity and bioethics," said Angela Foster and David Opderbeck, who served as special editors for the issue.

"The use of biotechnology has raised a number of legal, ethical and social issues, including who owns genetically modified organisms (GMOs), whether genetically modified foods are safe to eat, and who controls a person's genetic information. This issue explores contemporary biotechnology issues impacting the legal community."

A dozen articles explore the topic in the award-winning magazine, beginning with a look at whether organs-on-chips are patentable in an article by Douglas Bucklin. Richard Catalina Jr.'s article on the Biologics Price Competition and Innovation Act follows.

Nancy Del Pizzo's article looks at the open source model in biotechnology, while Foster explores the truth and fiction behind genetically modified food. Jonathan Lourie reviews strategic licenses and collaborations.

Reproduction is the topic of two articles, one analyzing assisted reproductive technology, written by Alan Milstein, and one penned by Kimberly Mutcherson on regulating the right to procreate.

Opderbeck's contribution focuses on synthetic biology and biosecurity, while Anjana Patel and Patricia Wagner discuss biotech mergers, acquisitions and antitrust issues and Marina Sigareva and Ryan O'Donnell look at global strategies for protecting biotech inventions.

The edition closes with articles on the Patent Trial and Appeal Board's influence on the biotech and pharma industries, written by Nichole Valeyko and Maegan Fuller, and the privacy implications for biotechnology by Wagner.

The October edition of New Jersey Lawyer will explore pro bono issues.

See the original post here:
NJSBA magazine explores biotechnology and genetics - Yahoo News

Posted in Biotechnology | Comments Off on NJSBA magazine explores biotechnology and genetics – Yahoo News

Should You Buy Puma Biotechnology (PBYI) Ahead of Earnings? August 04, 2017 – Zacks.com

Posted: August 6, 2017 at 5:42 am

Investors are always looking for stocks that are poised to beat at earnings season and Puma Biotechnology, Inc. (PBYI - Free Report) may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.

That is because Puma Biotechnology is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. After all, analysts raising estimates right before earningswith the most up-to-date information possibleis a pretty good indicator of some favorable trends underneath the surface for PBYI in this report.

In fact, the Most Accurate Estimate for the current quarter is currently at a loss of $2.03 per share for PBYI, compared to a broader Zacks Consensus Estimate of a loss of a $2.10 per share. This suggests that analysts have very recently bumped up their estimates for PBYI, giving the stock a Zacks Earnings ESP of +3.33% heading into earnings season.

Why is this Important?

A positive reading for the Zacks Earnings ESP has proven to be very powerful in producing both positive surprises, and outperforming the market. Our recent 10 year backtest shows that stocks that have a positive Earnings ESP and a Zacks Rank #3 (Hold) or better show a positive surprise nearly 70% of the time, and have returned over 28% on average in annual returns (see more Top Earnings ESP stocks here).

Given that PBYI has a Zacks Rank #3 (Hold) and an ESP in positive territory, investors might want to consider this stock ahead of earnings. You can seethe complete list of todays Zacks #1 Rank (Strong Buy) stocks here.

Clearly, recent earnings estimate revisions suggest that good things are ahead for Puma Biotechnology, and that a beat might be in the cards for the upcoming report.

Today's Stocks from Zacks' Hottest Strategies

It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.

And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation. See Them Free>>

Read the original post:
Should You Buy Puma Biotechnology (PBYI) Ahead of Earnings? August 04, 2017 - Zacks.com

Posted in Biotechnology | Comments Off on Should You Buy Puma Biotechnology (PBYI) Ahead of Earnings? August 04, 2017 – Zacks.com

20th World Congress on Biotechnology and Biotech Industries Meet – Technology Networks

Posted: August 6, 2017 at 5:42 am

20th World Congress on Biotechnology and Biotech Industries Meet during March 05-07, 2018 at London, UK with a theme Future prospects for Biotechnology and Economic Growth. Conference Series LLC through its Open Access Initiative is committed to make genuine and reliable contributions to the scientific community.

Scope and Importance

Biotech Congress 2018 Conference aims to bring together the Professors, Researchers, scientists, business giants, and technocrats to provide an international forum for the dissemination of original research results, new ideas and practical development and discover advances in the field of biotechnology, management and education in relation to biotechnology as well as a breadth of other topics. The applications of biotechnology include therapeutics, diagnostics, genetically modified crops for agriculture, processed food, bioremediation, waste treatment, and energy production. Biotech Congress 2018 is an excellent opportunity for the delegates from Universities and Institutes to interact with the world class Scientists.

Like what you just read? You can find similar content on the communities below.

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

Go here to see the original:
20th World Congress on Biotechnology and Biotech Industries Meet - Technology Networks

Posted in Biotechnology | Comments Off on 20th World Congress on Biotechnology and Biotech Industries Meet – Technology Networks

EBAL schools to raise funds for San Ramon Valley alum Jake Javier – SFGate

Posted: August 6, 2017 at 5:41 am

Its an event not ever seen or imagined around these parts. Not among rival East Bay football teams. Not this close to the season.

But members of four East Bay Athletic League squads along with Freedom-Oakley will gather at 5 p.m. Saturday at San Ramon Valley-Danville not to scrimmage, but to partake in family-reunion-type games like tug of war and three-legged races.

All of is it to honor and support Jake Javier, a former San Ramon Valley football player who is paralyzed from the chest down following a 2016 graduation pool-party diving accident.

Javier, an All-Metro two-way tackle bound for Cal Poly on a football scholarship, suffered life-threatening injuries, severe trauma to his vertebrae and nine months of extensive surgeries and rehabilitation before returning home in April.

Hes planning to pursue his dream to earn an engineering degree at Cal Poly with a special interest in stem-cell research. Javier had 10 million embryonic stem cells injected into his spine during one of the surgeries.

Hes a real special kid with a powerful message and he could use our help, said longtime De La Salle-Concord coach Bob Ladouceur, a San Ramon Valley graduate.

Ladouceur, who won 399 games as head coach at De La Salle (hes now an assistant) and is an NFHS Hall of Fame member, organized Saturdays Day of Games event that also includes the Spartans, Monte Vista-Danville and California-San Ramon.

Over a nearly 40-year career, Ladouceur felt very fortunate that none of his players endured catastrophic injury on the field. Javiers injury hit close to home, and affected Ladouceur deeply. When he read a Diablo magazine article detailing Javiers plight, Ladouceur felt compelled to do something about it.

He hopes to raise $100,000 through the Javi Strong Foundation to defray the huge medical and caregiving costs Javier and his family face.

Hes a remarkable young man, he really is, Ladouceur said. Hes optimistic, determined and motivated. We can all invest in his future.

The coaches and communities of all the teams are all in, which has touched Javier deeply.

Im just extremely grateful for the people in these communities who want to support me, over a year later, Javier told Prep2Preps Nate Smith. Coach Lad came out of nowhere with his idea to do something for me, so Im just really grateful for that support and generosity.

To support Javier, please go to http://app.eteamsponsor.com/ETS/supportUs/44369014.

New coach: One of those coaches, Monte Vistas Matt Russi, is the new head coach of the Mustangs, replacing Craig Bergman, who resigned to spend more time with his children, who play at California. Russi, a Monte Vista and Cal alum, was the teams defensive coordinator last season. Bergman, who just finished his 20th season with the schools sixth North Coast Section title, will continue to help with the offense and teach at the school.

Matt brings tremendous energy and a great mind to the table, said longtime assistant Chris Babcock. Were lucky to have him in the program. Its great to have a former Mustang take over for the reins.

Soldiers marching: After a surprising championship at the Nike EYBL Peach Jam final, the Oakland Soldiers lost 78-72 to Team Takeover (Washington, D.C.) in the final of the 8 AAU boys basketball championship Friday in Las Vegas.

Led by Salesian-Richmond guard James Akinjo, the Soldiers defeated Team Takeover in the final of the Peach Jam earlier in the month.

In a stunning 62-61 semifinal win Thursday over Team CP3, incoming St. Ignatius senior Darrion Trammell hit two free throws with two seconds left for the winning margin. Trammell came into the game for the first time only five seconds earlier after Akinjo fouled out. Team CP3, coached by NBA guard Chris Paul, led by as many as 14.

Thanks largely to his stellar summer play for the Soldiers, Akinjo, a 6-foot point guard, has 13 college offers including from Cal, Connecticut and Indiana.

Briefly: De La Salle, led by 2,000-yard rusher Kairee Robinson, USC-bound lineman Tuli Letuligasenoa and preseason junior All-America linebacker Henry Tootoo, is ranked 16th nationally by MaxPreps heading into the 2017 season. Menlo School-Atherton incoming 5-11 junior Selina Xu is one of 20 players selected to play for USA Volleyballs U18 training team. Menlos Jack Bowen was named as the National High School Coach of the Year by USA Water Polo.

MaxPreps senior writer Mitch Stephens covers high school sports for The San Francisco Chronicle.

Link:
EBAL schools to raise funds for San Ramon Valley alum Jake Javier - SFGate

Posted in Connecticut Stem Cells | Comments Off on EBAL schools to raise funds for San Ramon Valley alum Jake Javier – SFGate

John Theurer Cancer Center and MedStar Georgetown University Hospital Announce 100 – Business Wire (press release)

Posted: August 5, 2017 at 1:48 am

WASHINGTON & HACKENSACK, N.J.--(BUSINESS WIRE)--MedStar Georgetown University Hospital in Washington, D.C. in collaboration with John Theurer Cancer Center, part ofHackensack Meridian Health, Hackensack University Medical Center in Hackensack, N.J., announce the 100th blood stem cell transplant performed since the BMT programs first patient was treated in September, 2013.

The patient, a woman from Arlington, Virginia, received her blood stem cell transplant at MedStar Georgetown as a treatment for multiple myeloma diagnosed in December 2016.

The BMT program at MedStar Georgetown is a joint effort with specialists from Hackensack John Theurer Cancer Center and a key component of the Lombardi Comprehensive Cancer Center, the only cancer program in the Washington, D.C. region designated by the National Cancer Institute (NCI) as a comprehensive cancer center.

Once considered experimental, BMT is todays established gold standard for treating patients with a number of malignant and other non-malignant diseases of the immune system, blood, and bone marrow, including multiple myeloma, lymphoma, and acute and chronic leukemia. For some conditions, blood stem cell transplant can provide a cure in patients who have failed conventional therapies, says Scott Rowley, MD, chief of the BMT program at MedStar Georgetown as well as a member of the John Theurer Cancer Centers Blood and Marrow Stem Cell Transplantation. For some conditions, it can actually be a cure; for others, it prolongs survival and improves quality of life. Having performed 100 BMTs at MedStar Georgetown including allogenic transplantation illustrates the strength and maturity of our program achieved in rather short time.

MedStar Georgetowns program is also the only comprehensive BMT center within Washington, D.C. and southern Maryland with accreditation from the Foundation for the Accreditation of Cellular Therapy (FACT) for adult autologous procedures, where the patient donates his or her own cells.

The BMT program at JTCC is one of the top 10 transplant programs in the United States, with more than 400 transplants performed annually.

A BMT involves a two-step process: first, collecting bone marrow stem cells from the patient and storing them for future use. Then, a week or so later, patients receive high dose chemotherapy to eliminate their disease. The previously stored cells are reinfused back into the bloodstream, where after reaching the bone marrow, they begin repopulating and allow the patient to recover their blood counts over the following 2 weeks.

Even though BMT is considered standard therapy for myeloma worldwide, in the United States fewer than 50 percent of the patients who could benefit from BMT are referred for evaluation, says David H. Vesole, MD, PhD, Co- Chief and Director of Research of John Theurer Cancer Centers Multiple Myeloma division and director of MedStar Georgetowns Multiple Myeloma Program.

Thats mostly due to physicians concerns that a patient is too old or compromised from other health conditions like diabetes, cardiac disease or renal failure. But new techniques and better supportive care have improved both patient outcomes and the entire transplant process, extending BMT to more patients than ever before.

The MedStar Georgetown/Georgetown Lombardi Blood and Marrow Stem Cell Transplant Program is part of a collaborative cancer research agenda and multi-year plan to form an NCI-recognized cancer consortium. This recognition would support the scientific excellence of the two centers and highlight their capability to integrate multi-disciplinary, collaborative research approaches to focus on all the aspects of cancer.

The research areas include expansion of clinical bone marrow transplant research; clinical study of haplo transplants use of half-matched stem cell donor cells; re-engineering the function and focus of key immune cells; and the investigation of immune checkpoint blocking antibodies that unleash a sustained immune response against cancer cells.

In this partnership, weve combined John Theurers strength in clinical care with Georgetown Lombardis strong research base that significantly contributes to clinical excellence at MedStar Georgetown. By working together, we have broadened our cancer research to offer more effective treatment options for tomorrows patients, says Andrew Pecora, MD, FACP, CPE, president of the Physician Enterprise and chief innovations officer, Hackensack Meridian Health. This is one of many clinical and research areas that have been enhanced by this affiliation.

Our teams are pursuing specific joint research projects we feel are of the utmost importance and significance in oncology particularly around immuno-oncology as well as precision medicine, says Andr Goy, MD, MS, chairman of the John Theurer Cancer Center and director of the division chief of Lymphoma; chief science officer and director of Research and Innovation, RCCA; professor of medicine, Georgetown University. Together our institutions have a tremendous opportunity to transform the delivery of cancer care for our patient populations and beyond.

ABOUT THE JOHN THEURER CANCER CENTER AT HACKENSACK UNIVERSITY MEDICAL CENTER

John Theurer Cancer Center at Hackensack University Medical Center is New Jerseys largest and most comprehensive center dedicated to the diagnosis, treatment, management, research, screenings, and preventive care as well as survivorship of patients with all types of cancers. The 14 specialized divisions covering the complete spectrum of cancer care have developed a close-knit team of medical, research, nursing, and support staff with specialized expertise that translates into more advanced, focused care for all patients. Each year, more people in the New Jersey/New York metropolitan area turn to the John Theurer Cancer Center for cancer care than to any other facility in New Jersey. Housed within a 775-bed not-for-profit teaching, tertiary care, and research hospital, the John Theurer Cancer Center provides state-of-the-art technological advances, compassionate care, research innovations, medical expertise, and a full range of aftercare services that distinguish the John Theurer Cancer Center from other facilities.www.jtcancercenter.org.

MedStar Georgetown University Hospital is a not-for-profit, acute-care teaching and research hospital with 609 beds located in Northwest Washington, D.C. Founded in the Jesuit principle of cura personaliscaring for the whole personMedStar Georgetown is committed to offering a variety of innovative diagnostic and treatment options within a trusting and compassionate environment.

MedStar Georgetowns centers of excellence include neurosciences, transplant, cancer and gastroenterology. Along with Magnet nurses, internationally recognized physicians, advanced research and cutting-edge technologies, MedStar Georgetowns healthcare professionals have a reputation for medical excellence and leadership.

For more information please visit: medstargeorgetown.org/bmsct

About Hackensack Meridian Health Hackensack University Medical Center

Hackensack Meridian Health Hackensack University Medical Center, a 775-bed nonprofit teaching and research hospital located in Bergen County, NJ, is the largest provider of inpatient and outpatient services in the state. Founded in 1888 as the countys first hospital, it is now part of one of the largest networks in the state comprised of 28,000 team members and more than 6,000 physicians. Hackensack University Medical Center was listed as the number one hospital in New Jersey in U.S. News & World Reports 2016-17 Best Hospital rankings - maintaining its place atop the NJ rankings since the rating system was introduced. It was also named one of the top four New York Metro Area hospitals. Hackensack University Medical Center is one of only five major academic medical centers in the nation to receive Healthgrades Americas 50 Best Hospitals Award for five or more years in a row. Beckers Hospital Review recognized Hackensack University Medical Center as one of the 100 Great Hospitals in America 2017. The medical center is one of the top 25 green hospitals in the country according to Practice Greenhealth, and received 25 Gold Seals of Approval by The Joint Commission more than any other hospital in the country. It was the first hospital in New Jersey and second in the nation to become a Magnet recognized hospital for nursing excellence; receiving its fifth consecutive designation in 2014. Hackensack University Medical Center has created an entire campus of award-winning care, including: the John Theurer Cancer Center; the Heart & Vascular Hospital; and the Sarkis and Siran Gabrellian Womens and Childrens Pavilion, which houses the Joseph M. Sanzari Childrens Hospital and Donna A. Sanzari Womens Hospital, which was designed with The Deirdre Imus Environmental Health Center and listed on the Green Guides list of Top 10 Green Hospitals in the U.S. Hackensack University Medical Center is the Hometown Hospital of the New York Giants and the New York Red Bulls and is Official Medical Services Provider to The Northern Trust PGA Golf Tournament. It remains committed to its community through fundraising and community events especially the Tackle Kids Cancer Campaign providing much needed research at the Childrens Cancer Institute housed at the Joseph M. Sanzari Childrens Hospital. To learn more, visit http://www.HackensackUMC.org.

Read more:
John Theurer Cancer Center and MedStar Georgetown University Hospital Announce 100 - Business Wire (press release)

Posted in Virginia Stem Cells | Comments Off on John Theurer Cancer Center and MedStar Georgetown University Hospital Announce 100 – Business Wire (press release)

Roanoke researchers pursue treatments for the type of deadly brain cancer affecting McCain – Richmond.com

Posted: August 5, 2017 at 1:48 am

Researchers in Roanoke are developing ways to halt the insidious onslaught of the type of brain tumor affecting Arizona Sen. John McCain.

Brain cancers come in a lot of types and flavors. They go from benign and quite fixable to the very malignant and unfixable. The type that Sen. McCain has is unfortunately the very unfixable type, said Michael Friedlander, executive director of the Virginia Tech Carilion Research Institute and Techs vice president for health sciences and technology.

McCain was diagnosedlast month with glioblastoma, the type of brain cancer that scientists at VTCRI are specializing in. Their research is part of the institutes Center for Glial Biology in Health, Disease and Cancer. Glia were once considered the understudy to the brains star cells, neurons or nerve cells, and their role relegated to holding together the neurons. But more is being discovered about the role they play in brain health and diseases, including being the source of most malignant brain tumors.

When glial cells turn cancerous, they take on a unique property: the ability to shrink and slither elsewhere in the brain.

There are a big group of nerve fibers that connect the two halves of our brains called the corpus callosum, Friedlander explained. Its a bunch of white matter and fibers. And they will hop on that and cross over from one side of the brain to another. So the surgeon is over here, and he sees a tumor on an MRI, and he takes it out and does great surgery, getting every bit you can see.

Meanwhile, a couple hundred of those cells are on their way happily migrating to the other side of the brain. They work their way through these little spaces, take up residence and start dividing again. And now you have 10 brain tumors, and its inoperable at that point.

About 80,000 Americans each year are diagnosed with a primary brain tumor, meaning it originates in the brain and isnt from a cancer migrating from elsewhere in the body. There are 120 types of primary brain tumors, according to the American Brain Tumor Association. The vast majority are noncancerous, but since the brain is protected by a rigid, bony structure, even a benign tumor can cause damage by pressing on the brain.

About 26,000 of the new cases will involve a malignant tumor, with glioblastoma accounting for the majority of them.

Compared to lung cancer with 500,000 [people with the disease], its small, but the outcome is uniformly bad, Friedlander said. With the earliest, best diagnosis, by the time you have any symptoms, its big enough to be pushing on the brain and is already millions and millions of cells. So the cells have already moved out.

Most people live slightly more than a year following diagnosis.

Friedlander said theres no silver bullet under development. Rather, researchers are working on a cocktail of strategies.

Harald Sontheimer, the director of the institutes glial center, is working on a therapy that could freeze the migrating cells and another that would keep them from killing neurons, Friedlander said.

Researchers Rob Gourdie, Zhi Sheng and Samy Lamouille teamed up to see if they could make the glioblastoma cells receptive to temozolmide, the standard drug treatment, once it is no longer effective.

Sheng is a cancer researcher who discovered that one of the compounds Gourdie developed for heart disease and for healing bed sores appears to re-sensitize the cancer cells to the drug.

Gourdie said encouraging results in the lab have led them to begin trials on dogs at the Virginia-Maryland College of Veterinary Medicine. Dogs also form glioblastoma. The trial will help to determine if the combination is safe and effective enough to seek FDA approval for human trials.

We started last last year and have recruited a half dozen dogs so far. Its a slow process, Gourdie said.

Meanwhile, Lamouille was looking at whether other compounds would work to boost temozolmide, and he pulled from the freezer one Gourdie developed years ago but had set aside.

It had zero effect on the cancer, but something else happened: It killed off the stem cells, the ones that travel and form new tumors.

It was unexpected. We were kind of hoping the drug sensitivity thing would pan out, so you have to readjust your mindset to, 'Hang on, it's killing the cancer stem cells,' Gourdie said. Samy really has to take the credit for noticing that and building on it.

Gourdie and Lamouille formed a new company, Acomhal Research, to pursue development as a therapy for glioblastoma and to see whether the compound also kills stem cells for other types of cancer.

Friedlander said that while the lines of research show promise, it will take much more time, a commodity limited for people with glioblastoma.

The most telling thing in looking at how far behind we are in treating it is to look at some of the high-profile people who have had it and died from it, Friedlander said. Theres Sen. Ted Kennedy, Beau Biden and now Sen. McCain has it. These are people of high capacity, visibility and resources, and you can just imagine they or their families could pick up the phone and go to Mayo Clinic or Johns Hopkins or the best places in the country. The very best care available is woefully inadequate.

Link:
Roanoke researchers pursue treatments for the type of deadly brain cancer affecting McCain - Richmond.com

Posted in Virginia Stem Cells | Comments Off on Roanoke researchers pursue treatments for the type of deadly brain cancer affecting McCain – Richmond.com

Grant supports 3D innovation in stem cell-related cancer research at ODU – Southside Daily

Posted: August 5, 2017 at 1:48 am

Robert Bruno and Patrick Sachs, professors in ODUs School of Medical Diagnostic and Translational Sciences. (ODU News)

NORFOLK Robert Bruno and Patrick Sachs, professors in the School of Medical Diagnostic and Translational Sciences, recently received a $100,000 grant from the Jeffress Research Grants Program to further their efforts using biofabrication in stem cell-related research.

The grant is a first of its kind for Old Dominion University researchers in the College of Health Sciences.

Biofabrication, which allows scientists to create three-dimensional environments to study cellular interaction, has been a goal of Bruno and Sachs since they received a 3-D printer in 2013. The scientists along with doctoral student John Reid used the device to create its own attachments, converting it into a bioprinter. They then used the device to further develop their vision.

Understanding the basic mechanisms behind how stem cells develop into different cell types is critical for the generation of new therapies for cancer, tissue repair, and developmental disorders.

This proposal will adapt newly developed three-dimensional bioprinting technology to advance our understanding of this issue by carefully examining how cells confer different information to daughter cells during divisions, Bruno said.

The grant for Three-Dimensional Bioprinting for High-Throughput In-Vitro Modeling of Asymmetric Stem Cell Divisions was announced in late June.

We have received good feedback about the concepts of this approach for studying stem cell biology, however, the consistent critique was the development of preliminary experiments, Sachs said. This grant will be a critical stepping stone to help us establish this technique and secure larger federal funding.

The Jeffress Memorial Trust was founded in 1981 by Robert M. Jeffress in memory of his parents and is awarded to top schools in Virginia for research in chemical, medical or other scientific fields. The Jeffress Trust awards support high impact, innovative one-year projects that integrate computational and quantitative scientific methodologies across a broad range of scientific disciplines, according to its website.

Receiving such an award takes dogged determination, said Professor Roy Ogle, chair of the School of Medical Diagnostic and Translational Sciences. Its the type of grant that can require applicants to apply several times to receive.

Ogle was a Jeffress grant recipient while studying at the University of Virginia.

Im proud of Patrick and Robert for their persistence and thankful that the Jeffress Foundation, which was so instrumental in helping my career get started, is supporting these excellent scientists, he said.

In 2015, Bruno and Sachs received a prestigious Commonwealth Health Research Board (CHRB) grant in their study of cellular mutations that can lead to the increased risk of breast cancer in women and men. Bruno says that the stem cell will fuel the breast cancer research and vice versa.

The (breast cancer) project is about how the micro-environment controls cancer cells, Bruno said. This latest research deals with how the micro-environment controls stem cells. Two sides of the same coin.

Always be informed. Get the latest news and information delivered to your inbox

Original post:
Grant supports 3D innovation in stem cell-related cancer research at ODU - Southside Daily

Posted in Virginia Stem Cells | Comments Off on Grant supports 3D innovation in stem cell-related cancer research at ODU – Southside Daily

Page 1,500«..1020..1,4991,5001,5011,502..1,5101,520..»